The ␥-secretase complex catalyzes the final intramembraneous cleavage of the ␤-amyloid precursor protein, liberating the neurotoxic amyloid ␤-peptide implicated in Alzheimer's disease. Apart from the catalytic subunit presenilin (PS), three additional subunits, nicastrin, APH-1, and PEN-2, have been identified. In mammals, two PS homologues, PS1 and PS2, which are part of distinct ␥-secretase complexes, exist. Likewise, two APH-1 homologues, APH-1a and APH-1b, have been identified. Furthermore, two APH-1a splice forms, APH1aS and APH-1aL, have been reported. Here we show that both APH-1a splice forms and APH-1b are expressed in peripheral and neuronal cells. APH-1aS, APH-1aL, and APH-1b form separate, proteolytically active ␥-secretase complexes containing either one of the two PSs. Deficiency of APH-1a caused a decrease in nicastrin, PS, and PEN-2 levels and an increase in the levels of APH-1b, whereas deficiency of APH-1b did not affect the levels of APH-1a or the other complex components. Consistent with this finding, we found that deficiency of APH-1a was associated with reduced ␥-secretase activity, whereas deficiency of APH-1b was not. Thus, APH-1b ␥-secretase complexes may fulfill redundant functions. Taken together, our results suggest that, dependent on the tissue expression of the individual subunits, six distinct ␥-secretase complexes composed of the known subunits can exist in human cells.
Accumulation and deposition of the highly hydrophobic amyloid ␤-peptide (A␤) 1 in the brain is believed to cause a pathological cascade of neurotoxic events that ultimately leads to neurodegeneration in Alzheimer's disease (1) . A␤ is generated by proteolytic cleavage of the ␤-amyloid precursor protein (APP), a type I transmembrane protein, in two steps (2) . APP is first cleaved in its ectodomain by the aspartyl protease ␤-secretase, generating the membrane-retained C-terminal 99-amino acid fragment C99. C99 then becomes the substrate for a second aspartyl protease, ␥-secretase, which cleaves C99 in its transmembrane domain to release A␤ and the APP intracellular domain. Over the last few years it has been shown that ␥-secretase processes a number of other type I transmembrane proteins that undergo APP-like proteolytic processing (3) . Most notable among the other ␥-secretase substrates is the cell surface receptor Notch-1 (4). ␥-Secretase-mediated processing of Notch-1 liberates the Notch intracellular domain from the membrane, which upon nuclear translocation becomes involved in the transcriptional regulation of genes critical for cell fate decisions during development and adulthood (5) .
Biochemical studies, including one on functional reconstitution in yeast (6) , have demonstrated that proteolytically active ␥-secretase is a high molecular weight complex composed of at least four subunits (6 -10) . Presenilin (PS) is the catalytic subunit of the ␥-secretase complex harboring two aspartate residues in transmembrane domains 6 and 7 that define a novel active site closely resembling that of other recently identified polytopic aspartyl proteases (11) (12) (13) (14) (15) (16) (17) (18) . Within the ␥-secretase complex, PS occurs as a heterodimer of N-and C-terminal fragments (NTF/CTF) (19 -22) that may be generated by autoproteolysis (6, 12) . Additional subunits are the highly glycosylated type I transmembrane protein nicastrin (NCT) (23) (24) (25) and the polytopic membrane proteins APH-1 (6 -10, 26 -29) and PEN-2 (6 -10, 27, 30) . In mammalian cells, two PS homologues (PS1 and PS2) exist that are constituents of distinct ␥-secretase complexes (21, 30, 31) . Likewise, two homologues of APH-1, APH-1a and APH-1b, were identified (26, 27) . APH-1a exists in two C-terminal splice forms, the 247-amino acid splice variant APH-1aS and the 265-amino acid splice variant APH-1aL (27) (28) (29) . In addition, a single nucleotide deletion (C727) in the APH-1aS cDNA defines the 251-amino acid APH-1a variant, here termed APH-1aM (26, 27) . The APH-1a variants show ϳ56% amino acid identity to APH-1b. Assembly and maturation of the ␥-secretase occurs in a tightly regulated manner and depends on the availability of the individual components (2, 3) .
At present, the precise molecular architecture of the ␥-secretase complex is unknown. Depending on the experimental techniques and conditions used, the molecular mass of the complex has been estimated to be ϳ250 (8, 21, 32) , ϳ500 (9, 25, 30, 33, 34) , or even ϳ2000 kDa (9, 35) . Whereas a molecular mass of ϳ250 kDa approximates the molecular mass of the four components in a 1:1:1:1 stoichiometry, a ϳ500 kDa complex would be consistent with the presence of multimeric subunits or with the presence of additional, presently unidentified components. Indeed, evidence for a dimerization of the PS NTF/CTF heterodimer within the complex has recently been obtained (36, 37) . The larger complexes of ϳ2000 kDa that have been observed likely reflect multimerization of the smaller complexes under certain experimental conditions (9, 35) .
Because ␥-secretase complex formation and activity has mostly been studied under conditions of overexpression of the individual subunits (7, 8, 10, 38) , the molecular composition of endogenous ␥-secretase complexes remains not fully resolved. Regarding APH-1 in particular, only APH-1aL was identified in endogenous ␥-secretase complexes to date (9, 28, 29, 32, 39) . Thus, it remained unclear whether APH-1aS and APH-1b can also be identified in endogenous ␥-secretase complexes and, if so, whether APH-1a and APH-1b are part of identical or distinct ␥-secretase complexes. Here we address these questions and identify the APH-1a splice forms and APH-1b as constituents of distinct, proteolytically active ␥-secretase complexes.
EXPERIMENTAL PROCEDURES
Antibodies-The polyclonal antibodies 2021 and 434 were raised against the loop 3 domain (40) of APH-1a (residues 103-115) and affinitypurified using a GST-APH-1a (residues 57-115) fusion protein or raised against the C terminus of APH-1aL (residues 245-265) and affinitypurified using a GST-APH-1aL (207-265) fusion protein, respectively. The polyclonal antibody 435 was raised against the C terminus of APH-1b (residues 244 -257) and affinity-purified using a GST-APH-1b (residues 206 -257) fusion protein. The polyclonal and monoclonal antibodies against the PS1 N terminus (PS1N), the PS1 large loop (3027), the PS2 N terminus (BI.5D3), the PS2 large loop (BI.HF5c), and the PEN-2 N terminus (1638) were described previously (see Refs. 25 and 30 and citations therein). Antibodies against the C terminus of NCT (N1660), the FLAG epitope (M2), and the HA epitope (HA-7) were obtained from Sigma. Antibodies anti-penta-His and 6E10 (to A␤ 1-17) were obtained from Qiagen and Signet Laboratories, respectively.
cDNA Constructs-cDNAs encoding the 247-amino acid APH-1aS splice form and the 265-amino acid APH-1aL splice form as well as APH-1b were amplified from a human brain Matchmaker cDNA library (Clontech). cDNA encoding the 251-amino acid APH-1aM variant was generated by PCR-mediated mutagenesis of the APH-1aS cDNA. All APH-1 cDNAs were subcloned into pcDNA3.1/Zeo(ϩ) (Invitrogen) and verified by sequencing. For ␥-secretase reporter gene assays in yeast, cDNAs encoding HA-tagged APH-1aS and APH-1aL were generated and expressed as described (6) . In these assays, cDNA encoding the PS1 VRSQϩ isoform was used. To down-regulate APH-1a and APH-1b expression, appropriate hairpin oligonucleotides (41) corresponding to APH-1a-454 (5Ј-GACTCACCCTATTACTTCC-3Ј) or APH-1b-308 (5Ј-G-TATAAACCCAGGTGAGAC-3Ј) 5Ј-NAGN 17 YNN-3Ј target regions were cloned into pBSENU6 harboring the enhancer of the cytomegalovirus promoter in front of the U6 promoter to allow efficient expression of short hairpin RNA by RNA polymerase III (42) .
Cell Culture, Cell Lines, and Transfections-HEK293 cells stably expressing Swedish mutant APP 695 (HEK293/sw) (43) were cultured as described (25) . SH-SY5Y cells were cultured in Dulbecco's modified Eagle's medium/F-12 (1:1) (Cambrex) supplemented with 10% fetal calf serum and 1% penicillin/streptomycin. HEK293/sw cells were transiently or stably transfected with the indicated cDNAs using LipofectAMINE 2000 (Invitrogen) according to the instructions of the manufacturer. Stable APH-1a and APH-1b knock-down cells were generated by co-transfection of HEK293/sw cells with pBSENU6/APH-1a-454 or pBSENU6/APH-1b-308, respectively, and pcDNA3.1/Hygro(Ϫ) and selection for hygromycin (100 g/ml) resistance. Control cells were generated by stable co-transfection of pBSENU6 and pcDNA3.1/Hygro(Ϫ) and selected as above.
Protein Analysis-Membrane fractions of cultured cells were obtained by ultracentrifugation of postnuclear supernatant fractions from homogenates that were prepared as described (44) . For direct immunoblot analysis, membrane fractions were solubilized with STEN-lysis buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, and protease inhibitors (Sigma)). In addition, cell lysates that were prepared as described (45) were used for direct immunoblot analysis where indicated. For co-immunoprecipitation analysis, membrane fractions were solubilized in CHAPSO-lysis buffer (1% CHAPSO, 150 mM sodium citrate, pH 6.4, and protease inhibitors (Sigma)), subjected to a clarifying spin by ultracentrifugation, and incubated with the indicated antibodies and protein G-Sepharose for 2 h at 4°C. Following two washes in CHAPSO-wash buffer (0.5% CHAPSO and 150 mM sodium citrate, pH 6.4), the immunoprecipitates were subjected to immunoblot analysis.
␥-Secretase Assays-In vitro ␥-secretase assays using HEK293 cells and ␥-secretase reporter gene assays in yeast were carried out essentially as described (6) . For ␥-secretase reporter gene assays, a new reporter strain that expresses C 1-55 GAL4 lacking the FAD-associated V717I mutation was generated as described (6) .
RESULTS
To facilitate the characterization of the various forms of the ␥-secretase complex subunit APH-1 in more detail, we generated antibody 434 to the C terminus of the long splice form of APH-1a and antibody 435 to the C terminus of APH-1b (Fig.  1a) . In addition, we generated antibody 2021 to the loop 3 domain (40) of APH-1a as a pan-APH-1a antibody to allow detection of all APH-1a splice forms (Fig. 1a) . HEK293 cells stably expressing Swedish mutant APP (HEK293/sw) were transiently transfected with cDNAs encoding APH-1aS, APH1aM, APH-1aL, and APH-1b. Cell lysates were prepared and analyzed by immunoblotting with the above-described antibodies. As expected, antibody 434 specifically detected APH-1aL but not APH-1aS and APH-1aM (Fig. 1b) . In addition to the specific detection of the monomeric form of APH-1aL, aggregated forms were observed (Fig. 1b) . These aggregated forms were generally observed upon transient overexpression of APH-1 variants (Fig. 1, b, c, and d) . Endogenous APH-1aL was under the detection limit in cell lysates (Fig. 1b) . However, robust amounts of endogenous APH-1aL could be detected when membrane fractions of HEK293/sw cells were analyzed (Fig. 1b) . As expected, all three transiently expressed APH-1a splice forms were detected with the APH-1a antibody 2021 (Fig. 1c) . Similarly as with antibody 434, we failed to detect endogenous APH-1a with antibody 2021 in cell lysates, although it could be detected in membrane fractions of HEK293/sw cells (Fig. 1b) . Interestingly, the levels of APH-1aS were higher than the levels of APH-1aL in HEK293 cells, indicating that APH-1aS represents the major APH-1a splice variant in these cells (Fig. 1c) . No evidence for the existence of the APH-1aM variant in HEK293 cells was obtained (Fig. 1c,  lower section of panel) . The absence of the APH-1aM and the presence of the APH-1aS splice variant was confirmed by reverse transcription PCR coupled with AluI restriction analysis, which allowed us to distinguish these two isoforms because of the presence of an additional AluI site in the APH-1aM cDNA (data not shown). We next sought to identify APH-1b. As shown in Fig. 1d , immunoblotting with antibody 435 revealed the transiently expressed APH-1b. As expected, antibody 435 did not cross-react with the APH-1a variants (Fig 1d) . Again, as found for APH-1a, endogenous APH-1b was significantly enriched in membrane fractions (Fig. 1d ) of HEK293 cells. Immunoblotting of membrane fractions from SH-SY5Y cells with antibody 2021 demonstrated that both APH-1a splice forms and APH-1b are also expressed in a neuronal cell line (Fig. 1e) . In these cells, roughly similar amounts of APH-1aS and APH1aL were expressed. Reverse transcription PCR analysis revealed the presence of APH-1aS and the absence of APH-1aM mRNA in SH-SY5Y cells (data not shown). The abundance of APH-1aS and APH-1aL matched the abundance of the respective mRNA levels reported previously (8) .
Having demonstrated the specificity of our APH-1 antibodies, we next investigated the presence of APH-1a and APH-1b within ␥-secretase complexes. CHAPSO-solubilized membrane fractions of HEK293/sw cells were subjected to co-immunoprecipitation analysis with antibodies to NCT, PS1, or PS2. As shown in Fig. 2a , the antibody against NCT co-immunoprecipitated APH-1aS, APH-1aL, and APH-1b along with PEN-2 and the PS1 and PS2 NTF/CTF heterodimer. Likewise, APH-1aS, APH-1aL, APH-1b, NCT, and PEN-2 were co-immunoprecipitated with the PS1 and PS2 antibodies. Consistent with previous results (21, 30, 31) , the PS1 NTF/CTF heterodimer was not co-immunoprecipitated with the PS2 antibody and vice versa, demonstrating that separate ␥-secretase complexes exist that contain either one of the two PSs.
Although the above data strongly suggest that APH-1aS, APH-1aL, and APH-1b are components of distinct PS1 and PS2/␥-secretase complexes, they do not answer the question of whether APH-1a and APH-1b reside within the same ␥-secretase complexes. To address this question, we carried out coimmunoprecipitation analysis using antibodies 434 to APH1aL and 435 to APH-1b. As shown in Fig. 2b , antibody 434 to APH-1aL co-immunoprecipitated the PS1 and PS2 NTF/CTF heterodimer, PEN-2 and NCT, whereas neither APH-1aS nor APH-1b was co-immunoprecipitated. Similarly, antibody 435 to APH-1b co-immunoprecipitated the PS1 and PS2 NTF/CTF heterodimer, PEN-2 and NCT, but failed to co-immunoprecipitate APH-1aS or APH-1aL. Thus, these data show that APH1aS, APH-1aL, and APH-1b are constituents of distinct ␥-secretase complexes. We next analyzed the ␥-secretase activity associated with the APH-1a-and APH-1b-containing ␥-secretase complexes. CHAPSO-solubilized membrane fractions of HEK293/sw cells were subjected to co-immunoprecipitation with antibodies 434 to isolate APH-1aL-containing ␥-secretase complexes and with antibody 435 to isolate APH-1b-containing ␥-secretase complexes. The immunoprecipitated APH-1aL and APH-1b ␥-secretase complexes were then assayed for their ␥-secretase activity in vitro using recombinant APP-based C100-His 6 as a substrate. As shown in Fig. 3 , both ␥-secretase complexes processed C100-His 6 to A␤ and the APP intracellular domain. The cleavage occurred in a ␥-secretase-dependent manner as judged from its inhibition with the active site-directed ␥-secretase inhibitor L-685,458 (13) . Thus, the APH-1aL and APH-1b ␥-secretase complexes are both proteolytically active (Fig. 3a) . Because of the lack of an APH-1aS-specific antibody, we could not address the question of whether APH-1aS-containing ␥-secretase complexes are proteolytically active using the experimental set-up described above. We therefore made use of our previously established reporter gene assay to monitor reconstitution of ␥-secretase activity in yeast (6) in order to assess whether proteolytic activity is associated with an APH1aS-containing ␥-secretase complex. We thus coexpressed either C-terminally HA epitope-tagged APH-1aS or APH-1aL with PS1, NCT, N-terminally FLAG-epitope-tagged PEN-2, and the APP-based ␥-secretase reporter substrate C 1-55 -GAL4 (6) . Reconstitution of ␥-secretase activity causes the liberation of GAL4 from C 1-55 -GAL4, which, following its proteolytic release, acts a transcriptional activator of the Escherichia coli LacZ gene encoding ␤-galactosidase. As shown in Fig. 3b , we observed robust ␤-galactosidase activity upon coexpression of APH-1aS-HA with PS1, NCT, and FLAG-PEN-2. Consistent with previous results (6), robust ␤-galactosidase activity was also observed upon the coexpression of APH-1aL-HA with PS1, NCT, and FLAG-PEN-2, whereas no significant ␤-galactosidase activity was produced when the proteolytically inactive PS1 D385A was coexpressed instead of wild type PS1 as a negative control (Fig. 3b) . Expression of the ␥-secretase complex components was confirmed by immunoblotting of membrane fractions of the respective yeast strains (Fig. 3c) . Thus, these data show that a ␥-secretase complex containing APH-1aS is proteolytically active.
The above results show that the APH-1a and APH-1b ␥-secretase complexes are both proteolytically active. However, the results do not address the question of to which extent the APH-1a and APH-1b ␥-secretase complexes contribute to ␥-secretase activity. We therefore sought next to analyze the consequences of APH-1 down-regulation on the expression levels of the other ␥-secretase complex subunits and on ␥-secretase activity. We thus generated HEK293/sw cells in which either APH-1a or APH-1b expression was stably knocked down by RNA interference. Knock-down of APH-1a caused markedly reduced levels of NCT, the PS1 and PS2 NTFs, and PEN-2, whereas levels of APH-1b were increased (Fig. 4a) . In contrast, knock-down of APH-1b did not significantly affect the levels of the other ␥-secretase complex subunits. Consistent with the above observations, ␥-secretase activity was impaired in APH-1a knock-down cells but not in APH-1b knock-down cells FIG. 4 . Expression of ␥-secretase complex subunits is dependent on APH-1a but not on APH-1b expression. a, expression profiles of ␥-secretase complex components in APH-1a or APH-1b knockdown cells. Membrane fractions of HEK293/sw cells transfected with empty vector (control), APH-1a, or APH-1b knock-down cells were analyzed for levels of APH-1aS, APH-1aL, APH-1b, NCT, PS1, PS2, and PEN-2 by immunoblotting as described in the Fig. 2 legend. RNAi, RNA interference. b, knock-down of APH-1a but not of APH-1b impairs ␥-secretase activity. Cell lysates of cell lines described for panel a were analyzed for levels of APP CTFs by immunoblotting with antibody 6687. c, membrane fractions of HEK293/sw cells (control) or NCT knock-down cells (39) were analyzed for levels of APH-1aS, APH-1aL, APH-1b, and NCT by immunoblotting as described in the Fig. 2 legend.   FIG. 3 . APH-1a-and APH-1b-containing ␥-secretase complexes are proteolytically active. a, CHAPSO-solubilized membrane fractions from HEK293/sw cells were subjected to immunoprecipitation (IP) as described for Fig. 2b , and the immunoprecipitates were assayed for ␥-secretase activity in vitro using recombinant C100-His 6 as a ␥-secretase substrate. Where indicated, L-685,458 (200 nM) was present in the samples to inhibit ␥-secretase activity. A␤ and the APP intracellular domain (AICD) were analyzed by immunoblotting with antibody 6E10 and anti-penta-His, respectively. b, yeast strains expressing either GAL4 alone or coexpressing the indicated HA-tagged APH-1 variants with PS1 wild type (or inactive PS1 D385A, where indicated), NCT, FLAG-PEN-2, and the ␥-secretase reporter substrate C 1-55 -GAL4 were assayed for ␤-galactosidase activity. c, membrane fractions of the yeast strains described for panel b were analyzed for PS1, NCT, APH-1aS-HA, APH-1aL-HA, and FLAG-PEN-2 by immunoblotting with antibodies PS1N (to PS1), N1660 (to NCT), HA-7 (to the HA-epitope), and M2 (to the FLAG-epitope) respectively. holo, holoprotein.
as judged from the accumulation of APP CTFs upon the knockdown of APH-1a (Fig. 4b) . Interestingly, APH-1b levels were not down-regulated in NCT knock-down cells, whereas levels of APH-1a were strongly reduced (Fig. 4c) , consistent with previous results (45) . Taken together, these results show that, in HEK293 cells, APH-1b does not play a similar crucial role as that of APH-1a in ␥-secretase complex assembly and activity. DISCUSSION Our results show that the APH-1a splice variants as well as APH-1b do not undergo complex formation with each other but are constituents of distinct proteolytically active ␥-secretase complexes that contain either PS1 or PS2 as the catalytic subunit. Thus, dependent upon the tissue expression of the individual subunits, six distinct ␥-secretase complexes composed of the known subunits can exist in human cells. The presence of distinct ␥-secretase complexes raises the question of the regulation of their formation, the mechanism of their assembly, and their function. Previous studies showed that expression of the ␥-secretase complex subunits depends to some degree on their availability, such that the deficiency of a given subunit causes deficiency of the other subunits. This is because the subunits fail to become stabilized in the absence of their binding partners (2) . Exceptions to this coordinate regulation of expression are APH-1aL and NCT, which are comparatively stable in the absence of PS and PEN-2 (29, 34, 39, 46) , indicating a potential role of APH-1 and NCT as scaffolds for ␥-secretase complex assembly (7, 29, 32) . In this study we found that the expression of APH-1b is not dependent on the availability of the other ␥-secretase complex subunits, because APH-1b was not down-regulated when other ␥-secretase complex subunits such as APH-1a, NCT, or PEN-2 (data not shown) became limiting. Instead, under the limiting conditions of the other ␥-secretase complex subunits, APH-1b levels were maintained or even up-regulated as in APH-1a or PEN-2 knock-down cells (data not shown). Interestingly, the deficiency of APH-1b, in contrast to APH-1a, did not noticeably change the expression levels of the other ␥-secretase complex subunits. An influence of APH-1b on the levels of the other ␥-secretase complex components could only be detected when APH-1b was knocked down in combination with APH-1a in double knock-down cells (data not shown). Under these conditions, down-regulation of the other ␥-secretase complex components was more severe than that observed for the APH-1a knock-down alone. In that respect, APH-1b behaves similar to PS2, which is stable in the absence of PS1 (47, 48) and whose knock-out only affects the levels of the other complex subunits when PS1 is additionally knocked out (29, 30, 34, 39, 49) . Apart from this similarity, APH-1b behaves differently than PS2, as the deficiency of NCT or PEN-2 (data not shown) causes the deficiency of PS2 (and of PS1) but not of APH-1b. Our data therefore suggest that, at least in HEK293 cells, APH-1a acts as a major stabilizing partner for the other ␥-secretase complex subunits during assembly of the ␥-secretase complex, whereas APH-1b does not have a comparable stabilizing activity in ␥-secretase complex assembly in these cells. This finding may be due to a potential higher abundance of APH-1a as compared with APH-1b or that APH-1b has a weaker stabilizing activity than APH-1a for the other complex partners, or both. How APH-1b itself is stabilized is unclear at present but may possibly point to its own stability or to the presence of an additional cofactor, which selectively stabilizes APH-1b. Finally, our findings suggest that a knock-out of the APH-1a gene is expected to cause a Notch-deficient phenotype characteristic for PS1 or PS1/2 or NCT deficiency (33, 47, 48, 50 -52) , which may not be expected upon knock-out of the APH-1b gene.
Why do several distinct ␥-secretase complexes exist? A hint may come from a recent study that shows that the PS1 ␥-secretase complex displays greater activity than the PS2 ␥-secretase complex in the processing of C99 (53) . Thus, distinct ␥-secretase complexes may, in principle, have distinct affinities for the various ␥-secretase substrates and, thus, may process a given substrate with a distinct preference. Therefore, multiple ␥-secretase complexes may be required to accomplish both efficient recognition and efficient cleavage of all the various ␥-secretase substrates. In addition, because of its redundant activity the PS2 ␥-secretase complex can serve as a partial backup system for the PS1 ␥-secretase complex, at least in the processing of Notch and APP (47, 48, 53) . Because APH-1b ␥-secretase complexes can process APP-based substrates, they could potentially serve, at least partially, as a backup for APH-1a ␥-secretase complexes in APP processing. However, as shown in this study, maintenance or up-regulation of APH-1b was not sufficient to restore ␥-secretase activity under endogenous conditions.
The absence of mixed assemblies of PS1 with PS2 and APH-1a with APH-1b is consistent with the current models for the assembly of the ␥-secretase complex that suggest the formation of a trimeric PS, NCT, and APH-1 intermediate (Fig. 5) prior to the subsequent assembly of PEN-2 (7, 8, 10, 32, 54) . Once a trimeric intermediate of, for example, PS1, NCT, and APH-1a has been formed, the additional incorporation of PS2 or APH-1b may not be favored (probably due to their sequence differences), thus precluding the formation of mixed PS1/PS2 or APH-1a/APH-1b assemblies during ␥-secretase complex assembly. Instead, PEN-2 assembles to initiate PS endoproteolysis (7, 8, 10, 32, 54) . Following assembly, the four-component complexes may dimerize, thus providing the PS homodimers that have been observed (37) . Alternatively, the PS homodimers may have already been formed prior to or during ␥-secretase assembly. However, the observation that APH-1aL and APH-1aS do not form mixed complexes may indicate that a four-component ␥-secretase complex (or a single APH-1 protein alone) does not dimerize under endogenous conditions, although we cannot exclude the possibility that the difference in FIG. 5 . Model for the assembly of individual ␥-secretase complexes. NCT assembles with either of the individual APH-1 variants to form individual dimeric assembly intermediates. Next, either PS1 or PS2 holoprotein (holo) assembles to form individual trimeric intermediates. The subsequent assembly of PEN-2, which triggers PS endoproteolysis, completes ␥-secretase complex assembly. The scheme is based on current models for ␥-secretase complex assembly (see Refs. 55 and 56 for review and "Discussion" for details).
the C termini of APH-1aS and APH-1aL precludes dimerization. Thus, in future studies it will be important to clarify the subunit stoichiometry of ␥-secretase complexes. It will also be interesting to see whether the individual ␥-secretase complexes have preferred substrates.
